Features of acute COVID-19 associated with Post-Acute Sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study

Published: 14 July 2023| Version 3 | DOI: 10.17632/f234tpmp4y.3
Contributor:
IMPACC Network

Description

Post-acute sequelae of SARS-CoV-2 (PASC) is a significant public health concern. We describe Patient Reported Outcomes (PROs) on 590 participants prospectively assessed from hospital admission for COVID-19 through one year after discharge. Modeling identified 4 PRO clusters based on reported deficits (minimal, physical, mental/cognitive, and multidomain), supporting heterogenous clinical presentations in PASC, with sub-phenotypes associated with female sex and distinctive comorbidities. During the acute phase of disease, a higher respiratory SARS-CoV-2 viral burden and lower Receptor Binding Domain and Spike antibody titers were associated with both the physical predominant and the multidomain deficit clusters. A lower frequency of circulating B lymphocytes by mass cytometry (CyTOF) was observed in the multidomain deficit cluster. Circulating fibroblast growth factor 21 (FGF21) was significantly elevated in the mental/cognitive predominant and the multidomain clusters. Future efforts to link PASC to acute anti-viral host responses may help to better target treatment and prevention of PASC.

Files

Steps to reproduce

Please see our methods.

Institutions

  • University of Florida
  • Drexel University
  • Benaroya Research Institute at Virginia Mason
  • University of California Los Angeles
  • Icahn School of Medicine at Mount Sinai
  • University of California San Francisco
  • Yale University
  • University of Texas at Austin
  • Harvard Medical School
  • University of Arizona
  • Oregon Health and Science University Foundation
  • Stanford University
  • Baylor College of Medicine
  • Boston Children's Hospital
  • University of Oklahoma Health Sciences Center
  • Emory University School of Medicine

Categories

Immunology, Infectious Disease, Bioinformatics, Systems Biology, Big Data, COVID-19

Funders

  • National Institute of Allergy and Infectious Diseases
    United States
    Grant ID: 5R01AI135803-03;5U19AI118608-04;5U19AI128910-04;4U19AI090023-11;4U19AI118610-06;R01AI145835-01A1S1;5U19AI062629-17;5U19AI057229-17;5U19AI125357-05;5U19AI128913-03;3U19AI077439-13;5U54AI142766-03;5R01AI104870-07;3U19AI089992-09;5R01AI132774-03

Licence